Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDRH, LifeScience Alley Seek To Nationalize Reg Science Partnership

This article was originally published in The Gray Sheet

Executive Summary

“What we’re trying to achieve is a structure that goes beyond one-off projects, but rather to support a variety of different projects on an on-going basis,” CDRH Director Jeffrey Shuren said.

You may also be interested in...

Novel IP Policy Attracts Medical Device Research Funding At University Of Minnesota

The University of Minnesota’s Medical Devices Center, which just moved to a new 8,000 square-foot facility on the Minneapolis campus, is attracting great interest and investment from device makers. The director credits the university’s intellectual property policy for the success.

Washington Roundup, January 2013

The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.” This month we cover FDA’s proposal to require PMAs for metal-on-metal hips, the launch of the Medical Device Innovation Consortium, CMS draft guidance on CED, and a recent analysis of the potential impact of the Affordable Care Act on device markets.

Medical Device Innovation Consortium Launches, Aims To Start Projects In 2013

The first public-private partnership to focus on promoting medical device regulatory science, known as the Medical Device Innovation Consortium, aims to speed up patient access to medical device technologies.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts